Welcome to our dedicated page for Jaguar Health SEC filings (Ticker: JAGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Jaguar Health, Inc. (NASDAQ: JAGX) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures, giving investors structured access to its capital markets activity and material agreements. Jaguar is a commercial-stage pharmaceuticals company focused on plant-based prescription medicines for gastrointestinal distress in humans and animals, and its filings provide insight into how it finances and supports these programs.
Recent Form 8-K filings describe a range of transactions, including secured and unsecured promissory notes, royalty interest agreements and amendments, PIPE financings involving Series N Perpetual Preferred Stock and common stock with pre-funded warrants, and privately negotiated exchanges of preferred stock for common shares and pre-funded warrants. Other 8-Ks outline at-the-market offering amendments, conditional approval-related developments for Canalevia-CA1, and note purchase agreements backed by deposit account control arrangements and subsidiary guarantees.
Jaguar’s proxy materials, such as definitive proxy statements on Schedule 14A, detail stockholder proposals to approve share issuances under Nasdaq Listing Rule 5635(d), including common stock issuable upon exchange of Series L, Series M, and Series N preferred stock and upon conversion of certain convertible promissory notes and related warrants. These documents also explain voting rights, voting caps for preferred series, and the structure of special and annual meetings.
On this page, users can review Jaguar’s 10-K and 10-Q reports (when available) for broader business and risk disclosures, while Form 4 and related ownership filings provide visibility into insider equity transactions. Stock Titan enhances these filings with AI-powered summaries that highlight key terms in complex documents, such as interest rates, maturity dates, collateral arrangements, voting provisions, and share issuance conditions. Real-time updates from EDGAR ensure that new Jaguar Health filings, including 8-Ks announcing material events, are quickly accessible with plain-language explanations.
Jaguar Health, Inc. Schedule 13G/A discloses that CVI Investments, Inc. and Heights Capital Management, Inc. collectively report beneficial ownership of 147,000 shares, equal to 9.9% of the class. The filing states the reported shares consist of shares issuable upon exercise of warrants and that the warrants are not exercisable to the extent exercise would cause ownership to exceed 9.99%. The company's prospectus reported 1,324,471 shares outstanding (excluding shares underlying the warrants) as of June 13, 2025.
The filing shows shared voting and dispositive power of 147,000 shares and no sole voting or dispositive power. Heights Capital serves as investment manager to CVI and may be deemed to exercise voting and dispositive power over the shares; both reporting persons disclaim beneficial ownership except for their pecuniary interest. The statement is signed by Sarah Travis on 08/12/2025 and references previously filed Limited Power of Attorney and Joint Filing Agreement exhibits.
Jaguar Health, Inc. announced a Sixth Amendment to its At-The-Market (ATM) Offering Agreement that extends Lucid Capital Markets, LLC's role as a Manager under the agreement. The amendment extends Lucid's term retrospectively from June 30, 2025 to December 31, 2025, unless the parties agree to a further extension.
The amendment clarifies that if the agreement is not otherwise amended or extended, Ladenburg Thalmann & Co. Inc. will remain as the sole Manager after December 31, 2025. The company also filed a prospectus supplement (referencing the May 23, 2024 supplement and May 1, 2024 prospectus) relating to the amendment, and attached the full amendment as Exhibit 10.1.
Jaguar Health, Inc. filed Supplement No. 6 to its ATM Prospectus Supplement to amend the At-The-Market Offering Agreement with Ladenburg Thalmann and Lucid Capital Markets. The amendment, dated August 14, 2025, extends Lucid's role as a Manager under the ATM Agreement retrospectively from June 30, 2025 through December 31, 2025, unless further extended, after which Ladenburg would be the sole Manager.
Since the ATM Prospectus Supplement dated May 23, 2024, the company has sold 1,370,282 shares under the ATM Program for gross proceeds of approximately $22.9 million, leaving approximately $1.66 million available for future sales. The last reported Nasdaq sale price on August 13, 2025 was $2.59 per share.
Jaguar Health, Inc. reported total net revenue of $2.98 million for the quarter ended June 30, 2025 (product revenue $2.94M), up from $2.72M a year earlier, and $5.19 million for the six months ended June 30, 2025 versus $5.07M in 2024. Operating expenses rose to $11.0 million for the quarter, producing an operating loss of $8.01 million and a net loss of $10.56 million (six-month net loss $21.16 million).
On the balance sheet, cash fell to $2.21 million at June 30, 2025 from $8.00M at year-end; total assets were $48.27 million and total liabilities $41.39 million. The Company discloses an accumulated deficit of $367.35 million and states its current cash balances are not sufficient to fund its operating plan through one year, noting substantial doubt about continuing as a going concern. Financing during the six months provided $7.62M (including a $3.25M ATM and $3.45M of convertible notes). Revenue remains concentrated: two specialty pharmacy customers accounted for roughly ~88% of product revenue.
Jaguar Health, Inc. (Nasdaq: JAGX) has filed a Rule 424(b)(3) resale prospectus covering 507,390 shares of common stock that may be issued upon exercise of recently issued private-placement warrants. The registration allows the selling stockholders to freely resell: (i) 492,612 shares underlying common warrants priced at $5.84 per share and (ii) 14,778 shares underlying placement-agent warrants priced at $7.6125 per share. All warrants are immediately exercisable and expire on the earlier of (a) 24 months from the May 22 2025 issuance date, (b) a fundamental transaction, or (c) a liquidation event.
The company will receive no proceeds from secondary sales, but would collect up to roughly $3 million in gross proceeds if all warrants are exercised for cash. At the June 26 2025 closing price of $2.71, the warrants are out of the money, making near-term exercise unlikely and limiting immediate cash inflow. Nevertheless, the filing removes resale restrictions and may create an overhang on the stock once prices approach the exercise levels.
Investors should weigh the potential dilution of approximately 507 k shares against the modest, conditional capital infusion and review the company’s previously disclosed risk factors for additional context.
FAQ
What is the current stock price of Jaguar Health (JAGX)?
What is the market cap of Jaguar Health (JAGX)?
